Original BioMedicals Co., Ltd. engages in the development of drugs in Taiwan. The company develops OBM-A01, a radiation injury prevention and therapeutic drug for the treatment of acute radiation injuries, including nuclear radiation and solar radiation exposure in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for the treatment of iron deficiency. It also provides NE (vitamin C+E) and NE Butorphanol, as well as technical services. Original BioMedicals Co., Ltd. was incorporated in 2011 and is based in Tainan City, Taiwan.
Frequently asked questions
What sector does Original BioMedicals Co., Ltd. (6483) operate in?
Original BioMedicals Co., Ltd. belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Original BioMedicals Co., Ltd. (6483) current stock price?
As of the latest data, Original BioMedicals Co., Ltd. stock price is NT$13.95, with a previous close of NT$13.95.
What is Original BioMedicals Co., Ltd. (6483) current market capitalization?
Original BioMedicals Co., Ltd. market cap is approximately 928.92 million.
What is Original BioMedicals Co., Ltd. (6483) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.53.
Does Original BioMedicals Co., Ltd. (6483) pay dividends?
No. Original BioMedicals Co., Ltd. does not pay a dividend.
What is Original BioMedicals Co., Ltd. (6483) beta (volatility) score?
Original BioMedicals Co., Ltd. has a beta of 0.234, indicating lower volatility than the overall market.
